Universal Beteiligungs und Servicegesellschaft mbH Has $9.22 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
by Amy Steele · The Cerbat GemUniversal Beteiligungs und Servicegesellschaft mbH raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,027 shares of the company’s stock after purchasing an additional 7,183 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of Neurocrine Biosciences worth $9,218,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. USA Financial Formulas acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $25,000. Golden State Wealth Management LLC increased its holdings in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank acquired a new position in Neurocrine Biosciences in the third quarter worth approximately $27,000. Geneos Wealth Management Inc. raised its position in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Finally, Quent Capital LLC bought a new position in Neurocrine Biosciences during the third quarter valued at approximately $32,000. 92.59% of the stock is owned by institutional investors and hedge funds.
Neurocrine Biosciences Stock Down 0.0%
Shares of NBIX stock opened at $127.66 on Monday. Neurocrine Biosciences, Inc. has a 12 month low of $104.42 and a 12 month high of $160.18. The company has a market cap of $12.84 billion, a PE ratio of 27.39, a price-to-earnings-growth ratio of 0.67 and a beta of 0.35. The business’s 50 day moving average is $130.08 and its two-hundred day moving average is $137.96.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The firm had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.Neurocrine Biosciences’s quarterly revenue was up 28.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.69 earnings per share. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 6.33 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have commented on NBIX shares. HC Wainwright boosted their target price on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Canaccord Genuity Group raised their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Leerink Partners raised their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $173.00 to $185.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, BMO Capital Markets lowered their target price on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $180.45.
Check Out Our Latest Research Report on Neurocrine Biosciences
About Neurocrine Biosciences
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Further Reading
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).